815MO A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): Preliminary analysis on efficacy and safety
医学
奥比努图库单抗
内科学
肿瘤科
淋巴瘤
美罗华
作者
J-D. Xu,L-Y. Cheng,Jian Li,J-L. Zhuang,Z-X. Cheng,Y-H. Ren,Y-A. Zhang,Y. Wang,P. Liu